Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
Hsc70 Ameliorates the Vesicle Recycling Defects Caused by Excess α-Synuclein at Synapses.

  • Banks SML
  • Medeiros AT
  • McQuillan M
  • Busch DJ
  • Ibarraran-Viniegra AS
  • Sousa R
  • Lafer EM
  • Morgan JR
Prevalence of REM sleep behavior disorder in Sun City, Arizona.

  • Shprecher DR
  • Serrano GE
  • Zhang N
  • Intorcia A
  • Davis KJ
  • Glass M
  • Curry J
  • Walker J
  • Cutler B
  • Callan M
  • Garcia A
  • Sue LI
  • Beach TG
VAPB ER-Aggregates, A Possible New Biomarker in ALS Pathology.

  • Cadoni MPL
  • Biggio ML
  • Arru G
  • Secchi G
  • Orrù N
  • Clemente MG
  • Sechi G
  • Yamoah A
  • Tripathi P
  • Orrù S
  • Manetti R
  • Galleri G
Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease.

  • Ng ASL
  • Tan YJ
  • Lu Z
  • Ng EY
  • Ng SYE
  • Chia NSY
  • Setiawan F
  • Xu Z
  • Keong NCH
  • Tay KY
  • Au WL
  • Tan LCS
  • Tan EK
Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway.

  • Park JH
  • Burgess JD
  • Faroqi AH
  • DeMeo NN
  • Fiesel FC
  • Springer W
  • Delenclos M
  • McLean PJ
Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders.

  • Gmitterova K
  • Varges D
  • Schmitz M
  • Zafar S
  • Maass F
  • Lingor P
  • Zerr I
Brain MRI Reveals Ascending Atrophy in Parkinson's Disease Across Severity.

  • Blair JC
  • Barrett MJ
  • Patrie J
  • Flanigan JL
  • Sperling SA
  • Elias WJ
  • Druzgal TJ
Nanophotonic Platforms for Chiral Sensing and Separation.

  • Solomon ML
  • Saleh AAE
  • Poulikakos LV
  • Abendroth JM
  • Tadesse LF
  • Dionne JA
High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.

  • Bougea A
  • Stefanis L
  • Emmanouilidou E
  • Vekrelis K
  • Kapaki E
Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration.

  • Metzger JM
  • Matsoff HN
  • Zinnen AD
  • Fleddermann RA
  • Bondarenko V
  • Simmons HA
  • Mejia A
  • Moore CF
  • Emborg ME

Press releases, workshop summaries, and editorials

Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease

Shared platform to catalyze research collaboration toward biomarker discovery to advance the development disease therapies


The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.